Invex Therapeutics Share Price and Company Fundamentals



Price
$0.65
Change
0.090 (16.071%)
52 week
0.435 - 0.815

Last traded: Yesterday at 5:12 AM

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is headquartered in Subiaco, Australia.

Key Metrics

PE ratio

-

PB ratio

1.38

Dividend yield

0.00%

Beta

-

Market cap

-

Enterprise value

-

Company profile

Primary activitiesBiopharmaceuticals.
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.invextherapeutics.com
Mailing address38 Rowland Street Level 1 Subiaco WA 6008 Australia
Phone / Fax61 8 6382 0137 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

More: Invex Therapeutics Dividend history, yield and payout ratio

Dividend yield

0.00%

Dividend amount

$0.00

Payout ratio

0.00%

Invex Therapeutics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IXC dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

IXC's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Aug 2022, following are the company executives and directors listed on Invex Therapeutics.

NameTitleAgeTotal Pay
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLBCFO & Company Sec.130k
Prof. Alexandra Jean SinclairExec. Director & Chief Scientific Officer150k
Dr. Thomas Duthy M.B.A., Ph.D.Exec. Director124.97k

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-1,508.07%

Return on assets

-7.94%

Return on equity

-13.05%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Invex Therapeutics is and its enterprise value is .

Companies similar to Invex Therapeutics (IXC)

Invex Therapeutics (ASX:IXC) Frequently Asked Questions

1. What is Invex Therapeutics's Stock Symbol?

Invex Therapeutics trades on ASX under the ticker symbol "IXC".

2. What is Invex Therapeutics's stock price today?

One share of IXC stock can currently be purchased for approximately $0.65.

3. How can I contact Invex Therapeutics?

Invex Therapeutics's mailing address is 38 Rowland Street Level 1 Subiaco WA 6008 Australia. The company can be reached via phone at 61 8 6382 0137.

4. What is Invex Therapeutics's official website?

The official website of Invex Therapeutics is https://www.invextherapeutics.com.

5. Which share registry manages Invex Therapeutics's stock?

Invex Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.